French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

NEXT STORY
Helix BioPharma Corp. Closes $3.0 Million Private Placement
PREV STORY
Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Elekta redogör för förändringsprogrammetoch visar det senaste inom utvecklingsportföljen vidkapitalmarknadspresentationen på ASTRO

BOSTON, 26 september 2016 – Under dagens kapitalmarknadspresentation berättade Elektas (EKTA-B.ST) vd och koncernchef, Richard Hausmann, ...

author_avatar
NASDAQ Market News

Akari Therapeutics Announces Regulatory Progress Following FDA Meeting

NEW YORK and LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a ...

author_avatar
NASDAQ Market News

Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

author_avatar
NASDAQ Market News